Breast Cancer

The survival benefit with adjuvant chemotherapy in ER-negative breast cancer patients with isolated locoregional recurrence was sustained in the final analysis of the phase III CALOR trial.

Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses ovarian suppression in young women with hormone receptor (HR)-positive breast cancer.